Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) gapped up prior to trading on Tuesday following insider buying activity. The stock had previously closed at $7.09, but opened at $7.68. Kura Oncology shares last traded at $7.5350, with a volume of 524,723 shares changing hands.
Specifically, CEO Troy Wilson purchased 101,119 shares of the stock in a transaction dated Monday, November 16th. The stock was acquired at an average cost of $7.42 per share, for a total transaction of $750,302.98. Following the acquisition, the chief executive officer owned 635,456 shares of the company's stock, valued at $4,715,083.52. The trade was a 18.92% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Troy Wilson purchased 98,881 shares of the company's stock in a transaction that occurred on Friday, November 13th. The shares were purchased at an average cost of $7.63 per share, for a total transaction of $754,462.03. Following the completion of the transaction, the chief executive officer owned 534,337 shares in the company, valued at approximately $4,076,991.31. This represents a 22.71% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.
Analyst Ratings Changes
A number of equities analysts have commented on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Kura Oncology in a report on Wednesday, October 14th. Deutsche Bank set a $24.00 target price on shares of Kura Oncology in a report on Wednesday, October 14th. Morgan Stanley set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, August 24th. Citizens Jmp reaffirmed a "market outperform" rating and set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, August 24th. Finally, Raymond James Financial set a $24.00 price objective on shares of Kura Oncology in a research note on Monday, August 24th. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $25.88.
View Our Latest Analysis on Kura Oncology
Kura Oncology Price Performance
The company has a quick ratio of 4.71, a current ratio of 3.60 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $677.62 million, a P/E ratio of -2.24 and a beta of 0.56. The business has a 50 day simple moving average of $10.05 and a 200-day simple moving average of $9.76.
Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.04. Kura Oncology had a negative net margin of 369.26% and a negative return on equity of 336.24%. The company had revenue of $22.84 million during the quarter, compared to the consensus estimate of $24.94 million. Analysts predict that Kura Oncology, Inc. will post -3.20 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Kura Oncology in the 2nd quarter valued at about $115,286,000. Bank of America Corp DE bought a new stake in shares of Kura Oncology in the 2nd quarter worth approximately $12,735,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Kura Oncology during the second quarter valued at approximately $10,927,000. Aberdeen Group plc acquired a new stake in shares of Kura Oncology during the 3rd quarter valued at $8,443,000. Finally, Man Group plc acquired a new position in shares of Kura Oncology in the 2nd quarter valued at $4,749,000.
About Kura Oncology
(
Get Free Report)
Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company's best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kura Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kura Oncology wasn't on the list.
While Kura Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.